Home Based Daratumumab Administration for Patients With Multiple Myeloma

NCT05511428 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Plasma Cell Myeloma

Interventions

DRUG: Daratumumab and Hyaluronidase-fihj
OTHER: Questionnaire Administration
OTHER: Quality-of-Life Assessment
OTHER: Interview

Sponsor

Thomas Jefferson University

Collaborators

[object Object]